NasdaqGM:AUPHBiotechs
Aurinia Pharmaceuticals (NasdaqGM:AUPH): Valuation Insights Following Strong Q3 Results and Raised 2025 Guidance
Aurinia Pharmaceuticals (AUPH) just delivered a strong show for investors with better-than-expected third quarter results and an updated outlook for 2025. The company raised both its revenue and net product sales guidance, which suggests growing confidence in its business trajectory.
See our latest analysis for Aurinia Pharmaceuticals.
Aurinia Pharmaceuticals’ strong financial report and higher guidance have clearly energized the stock, with a 13% seven-day share price return and an...